% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rosenthal:280285,
      author       = {Rosenthal, Liana S and Farag, Mena and Aziz, N Ahmad and
                      Bang, Jee},
      title        = {{V}esicular monoamine transport inhibitors: current uses
                      and future directions.},
      journal      = {The lancet},
      volume       = {406},
      number       = {10503},
      issn         = {0140-6736},
      address      = {London [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DZNE-2025-00940},
      pages        = {650 - 664},
      year         = {2025},
      abstract     = {Advancements over the past decade in understanding
                      vesicular monoamine transporter 2 (VMAT2) inhibitors
                      highlight their key role in the treatment of movement and
                      neuropsychiatric disorders. VMAT2 is crucial for packaging
                      neurotransmitters such as serotonin, dopamine, and
                      norepinephrine into synaptic vesicles, facilitating their
                      release and reuptake in synaptic transmission. VMAT2
                      inhibitors, such as tetrabenazine, deutetrabenazine, and
                      valbenazine, show therapeutic efficacy in managing
                      hyperkinetic movement disorders, including Huntington's
                      disease, tardive dyskinesia, and Tourette's syndrome. These
                      inhibitors modulate excessive synaptic activity by reducing
                      neurotransmitter storage and release. Genetic variations,
                      particularly in the cytochrome P450 enzyme family, influence
                      VMAT2 inhibitor metabolism, necessitating personalised
                      dosing to optimise efficacy and minimise adverse events.
                      Recent studies have provided further structural insights
                      into VMAT2 inhibition mechanisms, paving the way for the
                      development of inhibitors with enhanced potency and
                      selectivity. Leveraging pharmacogenetics for precision
                      medicine and exploring VMAT2 inhibition in broader
                      therapeutic contexts could revolutionise treatment
                      frameworks for neurological and psychiatric conditions.},
      subtyp        = {Review Article},
      keywords     = {Humans / Vesicular Monoamine Transport Proteins:
                      antagonists $\&$ inhibitors / Vesicular Monoamine Transport
                      Proteins: metabolism / Tetrabenazine: analogs $\&$
                      derivatives / Tetrabenazine: therapeutic use /
                      Tetrabenazine: pharmacology / Huntington Disease: drug
                      therapy / Movement Disorders: drug therapy / Valine: analogs
                      $\&$ derivatives / Vesicular Monoamine Transport Proteins
                      (NLM Chemicals) / Tetrabenazine (NLM Chemicals) / SLC18A2
                      protein, human (NLM Chemicals) / deutetrabenazine (NLM
                      Chemicals) / valbenazine (NLM Chemicals) / Valine (NLM
                      Chemicals)},
      cin          = {AG Aziz},
      ddc          = {610},
      cid          = {I:(DE-2719)5000071},
      pnm          = {354 - Disease Prevention and Healthy Aging (POF4-354)},
      pid          = {G:(DE-HGF)POF4-354},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40783291},
      doi          = {10.1016/S0140-6736(25)01072-4},
      url          = {https://pub.dzne.de/record/280285},
}